Loader

Pathways

PathWhiz ID Pathway Meta Data

PW122384

Pw122384 View Pathway
disease

Cardiac Hypertophy

Rattus norvegicus

PW126148

Pw126148 View Pathway
physiological

Cardiac Cycle (Wiggers Diagram)

Homo sapiens
The Wiggers diagram is a tool used to teach cardiovascular physiology which typically includes pressure and volume changes during ventricular contractions (cardiac cycle). At the end of diastole (relaxation phase), the mitral valve closes and the left atrium contracts. When the left ventricular pressure exceeds aortic pressure, the aortic valve opens (systole), hits a peak and decreases as the volume in the left ventricle decreases. The aortic valve closes and slightly increases the pressure in the aorta (incisura). When the left ventricular pressure is below the left atrial pressure, the mitral valve opens and the left ventricle can begin filling with blood in order to repeat the process.

PW122383

Pw122383 View Pathway
disease

cardiac

Mus musculus

PW146206

Pw146206 View Pathway
drug action

Carboxymethylcellulose Drug Metabolism Action Pathway

Homo sapiens

PW175990

Pw175990 View Pathway
metabolic

Carboxin Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Carboxin are predicted with biotransformer.

PW145567

Pw145567 View Pathway
drug action

Carboxin Drug Metabolism Action Pathway

Homo sapiens

PW144554

Pw144554 View Pathway
drug action

Carboprost tromethamine Drug Metabolism Action Pathway

Homo sapiens

PW132324

Pw132324 View Pathway
metabolic

Carboprost tromethamine Drug Metabolism

Homo sapiens
Carboprost tromethamine is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Carboprost tromethamine passes through the liver and is then excreted from the body mainly through the kidney.

PW128625

Pw128625 View Pathway
drug action

Carboprost tromethamine Action Pathway

Homo sapiens
Carboprost tromethamine is a medication primarily used in obstetrics and gynecology for two distinct purposes. First, it is employed as an abortifacient agent in the second trimester of pregnancy, typically between the 13th and 20th weeks of gestation. This is indicated when other methods of abortion have not been successful or in specific conditions such as premature rupture of membranes or the need for a repeat instillation of the drug for fetal expulsion. Second, it is used for the treatment of postpartum uterine hemorrhage due to atony when conventional methods of management have not proven effective. In both scenarios, carboprost tromethamine stimulates myometrial contractions within the uterus, similar to labor contractions, which help evacuate the products of conception in the case of abortion and provide hemostasis in postpartum hemorrhage. However, it can also lead to side effects such as vomiting, diarrhea, transient temperature increases, and, in some cases, bronchoconstriction. It's important to note that the use of carboprost tromethamine for abortion is a medical procedure carried out under specific circumstances and should only be administered by trained healthcare professionals in a clinical setting. Additionally, its use should be closely monitored to ensure both the effectiveness of the treatment and the well-being of the patient.

PW145056

Pw145056 View Pathway
drug action

Carboplatin Drug Metabolism Action Pathway

Homo sapiens